# Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

> **NCT05631626** · PHASE3 · COMPLETED · sponsor: **Cingulate Therapeutics** · enrollment: 21 (actual)

## Conditions studied

- ADHD
- ADHD - Combined Type
- Attention Deficit Hyperactivity Disorder Combined
- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** CTx-1301 - Dexmethylphenidate 25mg
- **DRUG:** CTx-1301 - Dexmethylphenidate 37.5mg
- **DRUG:** CTx-1301 - Dexmethylphenidate 50mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05631626
- **Lead sponsor:** Cingulate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-06-13
- **Final completion:** 2023-06-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05631626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05631626, "Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05631626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*